Back to Trial

Oracle Runs

Oracle findings and outcome history for A Phase 2 Study of Orelabrutinib in Patients With Relapsing-Remitting Multiple Sclerosis (NCT04711148).

Runs
1
Findings
1
Latest Run
Apr 1, 2026, 7:13 PM
Resolution Evidence
Outcome
YES
Status
Resolved
Settlement Date
4/1/26 UTC
Executive Summary

Public sources clearly frame NCT04711148 as positive. A trial-specific report says the Phase 2 study was highly effective, with statistically significant primary-endpoint lesion reductions, and InnoCare later described the Phase II MS results as highly effective and used 80 mg QD to support Phase III selection.

Sources
Web Searchneurologylive.com2/27/25
BTK Inhibitor Orelabrutinib Shows Promising Efficacy in Phase 2 Study of Relapsing-Remitting Multiple Sclerosis

Trial-specific report on NCT04711148: orelabrutinib was described as highly effective; all active arms had statistically significant reductions in the primary endpoint at week 12, with 80 mg QD most effective.

View source
Sponsorbusinesswire.com3/27/25
InnoCare Releases 2024 Results and Business Highlights

Sponsor-linked summary says the Phase II MS results showed orelabrutinib was highly effective in RRMS, and 80 mg once daily had the best efficacy/safety profile and was selected for Phase III studies.

View source
All Oracle Findings

Every stored oracle finding for this trial, including pending, dismissed, rejected, superseded, and accepted items.

YESAccepted94% confidenceGPT-5.4 (OpenAI)

Will the results be positive?

Public sources clearly frame NCT04711148 as positive. A trial-specific report says the Phase 2 study was highly effective, with statistically significant primary-endpoint lesion reductions, and InnoCare later described the Phase II MS results as highly effective and used 80 mg QD to support Phase III selection.

Found Apr 1, 2026, 7:13 PMOutcome date Feb 27, 2025, 12:00 AMReviewed Apr 1, 2026, 7:16 PM
Web Searchneurologylive.comFeb 27, 2025, 12:00 AM
BTK Inhibitor Orelabrutinib Shows Promising Efficacy in Phase 2 Study of Relapsing-Remitting Multiple Sclerosis
Trial-specific report on NCT04711148: orelabrutinib was described as highly effective; all active arms had statistically significant reductions in the primary endpoint at week 12, with 80 mg QD most effective.
Sponsorbusinesswire.comMar 27, 2025, 12:00 AM
InnoCare Releases 2024 Results and Business Highlights
Sponsor-linked summary says the Phase II MS results showed orelabrutinib was highly effective in RRMS, and 80 mg once daily had the best efficacy/safety profile and was selected for Phase III studies.
Outcome History

Public history of accepted oracle reviews and recorded outcome changes for this trial.

Accepted Oracle Review (Legacy)Apr 1, 2026, 7:16 PM

Will the results be positive?

PendingtoYEScurrentYES
GPT-5.4 (OpenAI)94% confidenceReviewed Apr 1, 2026, 7:16 PM

Public sources clearly frame NCT04711148 as positive. A trial-specific report says the Phase 2 study was highly effective, with statistically significant primary-endpoint lesion reductions, and InnoCare later described the Phase II MS results as highly effective and used 80 mg QD to support Phase III selection.